All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| AGIO / Agios Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| CLVS / Clovis Oncology Inc
|
|
|
|
|
|
|
|
| BIB / ProShares Trust - ProShares Ultra Nasdaq Biotechnology Put
|
|
|
|
|
|
|
|
| PCRX / Pacira BioSciences, Inc.
|
|
|
|
|
|
|
|
| PGNX / Progenics Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| LOXO / Loxo Oncology, Inc.
|
|
|
|
|
|
|
|
| TSRO / TESARO, Inc.
|
|
|
|
|
|
|
|
| CFRX / ContraFect Corp
|
|
|
|
|
|
|
|
| MEIP / MEI Pharma, Inc.
|
|
|
|
|
|
|
|
| XBI / SPDR Series Trust - SPDR S&P Biotech ETF
|
|
|
|
|
|
|
|
| MDCO / Medicines Company
|
|
|
|
|
|
|
|
| BIB / ProShares Trust - ProShares Ultra Nasdaq Biotechnology
|
|
|
|
|
|
|
|
| PRTK / Paratek Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
| BLUE / bluebird bio, Inc.
|
|
|
|
|
|
|
|
| US0153511094 / Alexion Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| KPTI / Karyopharm Therapeutics Inc.
|
|
|
|
|
|
|
|
| SGEN / Seagen Inc
|
|
|
|
|
|
|
|
| ALNY / Alnylam Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| SCYX / SCYNEXIS, Inc.
|
|
|
|
|
|
|
|
| PGEN / Precigen, Inc.
|
|
|
|
|
|
|
|
| AVXS / AveXis, Inc.
|
|
|
|
|
|
|
|
| UTHR / United Therapeutics Corporation
|
|
|
|
|
|
|
|
| ADMS / Adamas Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| AKBA / Akebia Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ALKS / Alkermes plc
|
|
|
|
|
|
|
|
| IQV / IQVIA Holdings Inc.
|
|
|
|
|
|
|
|
| ILMN / Illumina, Inc.
|
|
|
|
|
|
|
|
| ACAD / ACADIA Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
| VRTX / Vertex Pharmaceuticals Incorporated
|
|
|
|
|
|
|
|
| NBIX / Neurocrine Biosciences, Inc.
|
|
|
|
|
|
|
|
| BIIB / Biogen Inc.
|
|
|
|
|
|
|
|
| TECH / Bio-Techne Corporation
|
|
|
|
|
|
|
|
| IBB / iShares Trust - iShares Biotechnology ETF
|
|
|
|
|
|
|
|
| REPH / Societal CDMO Inc
|
|
|
|
|
|
|
|
| CKPT / Checkpoint Therapeutics, Inc.
|
|
|
|
|
|
|
|
| FGEN / FibroGen, Inc.
|
|
|
|
|
|
|
|
| INCY / Incyte Corporation
|
|
|
|
|
|
|
|
| CRL / Charles River Laboratories International, Inc.
|
|
|
|
|
|
|
|
| GILD / Gilead Sciences, Inc.
|
|
|
|
|
|
|
|
| BMRN / BioMarin Pharmaceutical Inc.
|
|
|
|
|
|
|
|
| GRFS / Grifols, S.A. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| EXEL / Exelixis, Inc.
|
|
|
|
|
|
|
|
| CELG / Celgene Corp.
|
|
|
|
|
|
|
|
| MTD / Mettler-Toledo International Inc.
|
|
|
|
|
|
|
|
| QGEN / Qiagen N.V.
|
|
|
|
|
|
|
|
| IONS / Ionis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| NKTR / Nektar Therapeutics
|
|
|
|
|
|
|
|
| RARE / Ultragenyx Pharmaceutical Inc.
|
|
|
|
|
|
|
|
| PRQR / ProQR Therapeutics N.V.
|
|
|
|
|
|
|
|
| AMGN / Amgen Inc.
|
|
|
|
|
|
|
|
| ICPT / Intercept Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| REGN / Regeneron Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| AXSM / Axsome Therapeutics, Inc.
|
|
|
|
|
|
|
|
